News | August 11, 2024
HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
Our centers are performing as expected or even better
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
